Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
follitropin delta + hMG
- Development stage
- Unknown
- Lead developer
- Ferring Pharmaceuticals
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Follitropin delta + hMG is a combination gonadotropin regimen used for controlled ovarian stimulation (COS) in women undergoing assisted reproductive technologies (ART), such as in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI). Follitropin delta (Rekovelle) is a recombinant follicle-stimulating hormone (rFSH) produced in a human cell line (PER.C6), which allows for individualized dosing based on a patient's serum anti-Müllerian hormone (AMH) levels and body weight. Human menopausal gonadotropin (hMG, e.g., Menopur) is a purified extract from the urine of postmenopausal women that contains both FSH and luteinizing hormone (LH) activity. By combining these two agents, the regimen provides comprehensive stimulation of both FSH and LH receptors, aiming to optimize follicular development, oocyte yield, and embryo quality, particularly in populations such as advanced-age women who may benefit from LH supplementation.
- Brand names
- RekovelleMenopur
- Other names
- follitropin delta + human menopausal gonadotropinrFSH + hMG
02
Targets
FSHR (Follicle-stimulating hormone receptor)LHCGR (Luteinizing hormone/choriogonadotropin receptor)
Beyond the preview
Go deeper on follitropin delta + hMG.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on follitropin delta + hMG.